Tech Note

AN 11 RESIN REPLACEMENT STUDY

Resin Replacement Study Using JSR Amsphere™ A3 and a Platform Resin to Reduce the Supply Risk of Protein A Resin

Amsphere A3 resin is currently involved in over 95 clinical phase trials. Independent studies have confirmed its productivity and competitiveness  Given the wide range of targets (such as mAb/Fc-fusion/Fab) and processing conditions for which it performs well, Amsphere A3 can be considered a “universal” affinity resin for the processing of antibody-based biopharmaceuticals. Biopharmaceutical companies have long been concerned with preserving security of supply of both products and consumables, including chromatography resins.